Cover Image
市場調查報告書

RegenxBio Inc.:產品平台分析

RegenxBio Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 341864
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
RegenxBio Inc.:產品平台分析 RegenxBio Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 35 Pages
簡介

RegenxBio Inc.(原 ReGenX Biosciences LLC.)是開發及提供各種疾病的治療藥的生物製藥公司。該公司的遺傳基因通知技術的NAV,有獨特的基因重組腺結合病毒媒介。還有該公司也提供代謝性疾病、肌病變、血液疾病、神經退化性疾病等疾病的治療藥。

本報告提供RegenxBio Inc.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估及暫停中的計劃相關資訊等

RegenxBio Inc.的基本資料

  • RegenxBio Inc.概要
  • 主要資訊
  • 企業資料

RegenxBio Inc.:R&D概要

  • 主要的治療範圍

RegenxBio Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

RegenxBio Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

RegenxBio Inc.:藥物簡介

RegenxBio Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

RegenxBio Inc.:最近的開發平台趨勢

RegenxBio Inc.:暫停中的計劃

RegenxBio Inc.:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC07556CDB

Summary

Global Markets Direct's, 'RegenxBio Inc. - Product Pipeline Review - 2015', provides an overview of the RegenxBio Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RegenxBio Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of RegenxBio Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of RegenxBio Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the RegenxBio Inc.'s pipeline products

Reasons to buy

  • Evaluate RegenxBio Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of RegenxBio Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the RegenxBio Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of RegenxBio Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of RegenxBio Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of RegenxBio Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RegenxBio Inc. Snapshot
    • RegenxBio Inc. Overview
    • Key Information
    • Key Facts
  • RegenxBio Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • RegenxBio Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • RegenxBio Inc. - Pipeline Products Glance
    • RegenxBio Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • RegenxBio Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • RegenxBio Inc. - Drug Profiles
    • Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-314
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RegenxBio Inc. - Pipeline Analysis
    • RegenxBio Inc. - Pipeline Products by Target
    • RegenxBio Inc. - Pipeline Products by Route of Administration
    • RegenxBio Inc. - Pipeline Products by Molecule Type
    • RegenxBio Inc. - Pipeline Products by Mechanism of Action
  • RegenxBio Inc. - Recent Pipeline Updates
  • RegenxBio Inc. - Dormant Projects
  • RegenxBio Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RegenxBio Inc., Key Information
  • RegenxBio Inc., Key Facts
  • RegenxBio Inc. - Pipeline by Indication, 2015
  • RegenxBio Inc. - Pipeline by Stage of Development, 2015
  • RegenxBio Inc. - Monotherapy Products in Pipeline, 2015
  • RegenxBio Inc. - Partnered Products in Pipeline, 2015
  • RegenxBio Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • RegenxBio Inc. - Out-Licensed Products in Pipeline, 2015
  • RegenxBio Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • RegenxBio Inc. - Phase I, 2015
  • RegenxBio Inc. - Preclinical, 2015
  • RegenxBio Inc. - Pipeline by Target, 2015
  • RegenxBio Inc. - Pipeline by Route of Administration, 2015
  • RegenxBio Inc. - Pipeline by Molecule Type, 2015
  • RegenxBio Inc. - Pipeline Products by Mechanism of Action, 2015
  • RegenxBio Inc. - Recent Pipeline Updates, 2015
  • RegenxBio Inc. - Dormant Developmental Projects,2015

List of Figures

  • RegenxBio Inc. - Pipeline by Top 10 Indication, 2015
  • RegenxBio Inc. - Pipeline by Stage of Development, 2015
  • RegenxBio Inc. - Monotherapy Products in Pipeline, 2015
  • RegenxBio Inc. - Out-Licensed Products in Pipeline, 2015
  • RegenxBio Inc. - Pipeline by Top 10 Target, 2015
  • RegenxBio Inc. - Pipeline by Top 10 Route of Administration, 2015
  • RegenxBio Inc. - Pipeline by Top 10 Molecule Type, 2015
  • RegenxBio Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top